Table 3.
CHIKV neutralization antibody rate. The table shows the proportion of patients with neutralizing antibodies for each factor (gender, age groups, regions, years, and clinical diagnoses). The Chi-square or Fisher’s exact test was used to compare the difference in the proportion of neutralizing antibodies between groups within each factor. The factors with statistically significant differences are analyzed in more detail in the following sections.
| Variable | Patients n (%) + |
FRNT50
n (%) ++ |
p Value (χ² or Fisher Test) |
|---|---|---|---|
| Gender | |||
| Female | 470 (44.2) | 54 (11.5) | 0.32 |
| Male | 593 (55.8) | 57 (9.6) | |
| Age groups | |||
| ≤5 | 136 (12.8) | 19 (14) | <0.0001 |
| 6–15 | 423 (39.8) | 34 (8) | |
| 16–45 | 382 (35.9) | 21 (5.5) | |
| ≥46 | 122 (11.5) | 37 (30.3) | |
| Regions | |||
| North | 283 (26.6) | 21 (7.4) | 0.052 |
| South | 780 (73.4) | 90 (11.5) | |
| Year of illness * | |||
| 2017 | 368 (34.6) | 39 (10.6) | 0.991 |
| 2018 | 326 (30.7) | 34 (10.4) | |
| 2019 | 369 (34.7) | 38 (10.3) | |
| Clinical diagnoses ** | |||
| Non-specific febrile illness | 361 (34) | 36 (10) | 0.14 |
| Suspected Dengue | 58 (5.5) | 8 (13.8) | |
| Dengue without warning sign | 604 (56.8) | 62 (10.3) | |
| Dengue with warning sign | 26 (2.4) | 1 (3.8) | |
| Severe Dengue | 14 (1.3) | 4 (28.6) | |
| Overall | 1063 (100) | 111 (10.4) | |
+ % in total for each variable. ++ % in each lane. * Age groups were defined based on the date and year of illness. ** Clinical diagnoses identified on patient’s initial hospital visit.